BHST on Nasdaq
BIOHARVEST SCIENCES INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Verrica Pharmaceuticals Inc., Earth Science Tech, Inc. or Arcus Biosciences, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
59.3%Gross margin2
-16.2%Operating margin2
-32.3%Net margin2
37.0%Revenue growth, 20252
-43.8%Return on equity2
-$9.6MFree cash flow2
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Business segments
North America brought in 84% of the revenue BIOHARVEST SCIENCES INC. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2024 | 2025 |
|---|---|---|
| North America | $23.0M | $30.6M |
| Israel | $2.2M | $3.9M |
| CDMO Services | $282.0K | $1.9M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue41¢$14.0M
- Other costs59¢$20.4M
- Income tax0¢$76.0K
Out of $34.5M in revenue.2 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenues | $34.5M | $25.2M |
| Cost of revenues | -$14.0M | -$11.2M |
| Gross profit | $20.5M | $13.9M |
| Research and development | -$5.3M | -$4.8M |
| Sales and marketing | -$15.8M | -$11.7M |
| General and administrative | -$4.9M | -$4.4M |
| Total operating expenses | -$26.1M | -$20.9M |
| Operating loss | -$5.6M | -$7.0M |
| Finance income | $54.0K | $0 |
| Finance expenses | -$5.5M | -$5.9M |
| Net loss before tax | -$11.1M | -$12.9M |
| Taxes on income | -$76.0K | -$8.0K |
| Net loss and comprehensive loss | -$11.1M | -$12.9M |
| Basic and diluted loss per share | -$0.60 | -$0.80 |
| Weighted average number of shares outstanding | 18.4M shares | 16.2M shares |
No quarterly figures reported.
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cash and cash equivalents | $23.0M | $2.4M |
| Trade accounts receivable | $2.0M | $1.1M |
| Other accounts receivable | $935.0K | $695.0K |
| Inventory | $4.6M | $3.7M |
| Total current assets | $30.5M | $7.9M |
| Restricted cash | $433.0K | $371.0K |
| Property, plant and equipment, net | $8.3M | $7.8M |
| Right-of-use assets, net | $8.4M | $9.0M |
| Total non-current assets | $17.2M | $17.1M |
| Total assets | $47.7M | $25.0M |
| Trade accounts payable | $2.6M | $3.5M |
| Other accounts payable | $2.2M | $3.6M |
| Deferred revenue | $492.0K | $906.0K |
| Lease liabilities | $1.4M | $772.0K |
| Loans | $149.0K | $3.9M |
| Liability for Agricultural Research Organization | $452.0K | $1.1M |
| Accrued liabilities | $386.0K | $401.0K |
| Total current liabilities | $7.7M | $14.3M |
| Lease liabilities | $10.1M | $9.1M |
| Liability for Agricultural Research Organization | $2.0M | $272.0K |
| Total non-current liabilities | $14.5M | $9.4M |
| Share capital and contributed surplus | $133.0M | $97.7M |
| Accumulated deficit | -$107.6M | -$96.4M |
| Total Shareholders' equity | $25.4M | $1.3M |
| Total liabilities and shareholders' equity | $47.7M | $25.0M |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$11.1M | -$12.9M |
| Depreciation and Amortization | $1.6M | $1.3M |
| Fair value adjustments of Convertible loans | $0 | $3.5M |
| Fair value adjustments of derivative liability - Warrants | $0 | $408.0K |
| Re-assessment of Liability for Agricultural Research Organization | -$396.0K | -$205.0K |
| Interest over Agricultural Research Organization liability | $270.0K | $403.0K |
| Finance expense (income), net | $3.8M | $823.0K |
| Share based compensation | $597.0K | $601.0K |
| Change in Trade accounts receivable | -$865.0K | -$308.0K |
| Change in Other accounts receivable | -$240.0K | -$286.0K |
| Change in Inventory | -$904.0K | -$1.2M |
| Changes in Trade accounts payable, Other accounts payable and Accrued liabilities | $482.0K | $1.0M |
| Changes in deferred revenue | -$415.0K | $188.0K |
| Net cash used in operating activities | -$7.2M | -$6.7M |
| Purchase of property and equipment | $2.4M | $2.8M |
| Deposit of restricted cash for bank guarantee, net of drawing | -$10.0K | -$192.0K |
| Net cash used in investing activities | -$2.4M | -$3.0M |
| Repayments of lease liabilities | -$1.4M | -$579.0K |
| Proceeds from loans | $12.4M | $3.4M |
| Repayments of Convertible Loans (principal and interest) | $0 | -$693.0K |
| Proceeds from exercise of investor warrants, net of finder fees | $6.8M | $0 |
| Net proceeds from issuance of units of securities in private placement | $0 | $4.3M |
| Repayment of royalties' liability to the Agricultural Research Organization | -$159.0K | $0 |
| Net proceeds from issuance of shares in public offering | $18.3M | $0 |
| Proceeds from exercise of stock options | $36.0K | $408.0K |
| Net cash provided by financing activities | $30.2M | $6.8M |
| Exchange rate differences on cash and cash equivalents | $39.0K | -$34.0K |
| Increase (decrease) in cash and cash equivalents | $20.6M | -$2.9M |
| Conversion of convertible loans into equity | $7.6M | $20.5M |
| Exercise of investor warrants by settlement of an outstanding debt | $1.8M | $0 |
| Reclassification of warrants as an equity instrument | $0 | $934.0K |
| Purchase of property under installment payment agreement | $0 | $1.4M |
| Recognition of right-of-use assets and lease liabilities | $399.0K | $8.4M |
| Taxes paid | $39.0K | $45.0K |
Former names
Recent filings
- Oct 13, 20266-K REPORT
- Oct 8, 20266-K REPORT
- Oct 2, 20266-K REPORT
- Sep 15, 20266-K REPORT
- Sep 15, 20266-K REPORT
- Sep 14, 20266-K REPORT
- Sep 3, 20266-K REPORT
- Aug 12, 20266-K REPORT
- Aug 11, 20266-K REPORT
- Jul 29, 20266-K REPORT
- Jul 28, 20266-K REPORT
- Jul 16, 20266-K REPORT
- Jul 15, 20266-K REPORT
- Jun 18, 20266-K REPORT
- May 28, 20266-K REPORT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4